Tenaya Reports Positive TN-201 Gene Therapy Data in MYBPC3-Associated HCM
SOUTH SAN FRANCISCO, Calif., June 3, 2026 Tenaya Therapeutics announced new interim data from its ongoing MyPEAK™-1 Phase 1b/2...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SOUTH SAN FRANCISCO, Calif., June 3, 2026 Tenaya Therapeutics announced new interim data from its ongoing MyPEAK™-1 Phase 1b/2...
SOUTH SAN FRANCISCO, Calif., June 2, 2026 Tenaya Therapeutics announced that it will present new interim clinical data from...
